Table 1.
Baseline characteristic of enrolled patients.
| Fibrosis Stage 0–2 (N = 31) |
Fibrosis Stage 3–4 (N = 33) |
p Value ** | |
|---|---|---|---|
| Sex | 0.322 # | ||
| Male | 20 (64.5) | 26 (78.8) | |
| Female | 11 (35.5) | 7 (21.2) | |
| Mean age (±SD) | 54.2 (±11.3) | 50.9 (±8.2) | 0.186 $ |
| Etiology | 0.586 ^ | ||
| CHB | 21 (67.7) | 25 (75.8) | |
| CHC | 2 (6.5) | 0 (0.0) | |
| Alcohol | 3 (9.7) | 2 (6.1) | |
| Others | 5 (16.1) | 6 (18.2) | |
| Diabetes | 6 (19.4) | 11 (33.3) | 0.326 # |
| BMI | 0.085 # | ||
| ≤25 kg/m2 | 25 (80.7) | 19 (57.6) | |
| >25 kg/m2 | 6 (19.4) | 14 (42.4) | |
| ALT | 1.000 # | ||
| ≥31 (F), ≥41 (M) IU/L | 12 (38.7) | 13 (39.4) | |
| AST | 1.000 # | ||
| ≥31 (F), ≥37 (M) IU/L | 19 (61.3) | 20 (60.6) | |
| GGT | (−5) | (−1) | 0.640 # |
| ≥50 (IU/L) | 18 (58.1) | 25 (78.1) | |
| Albumin | 0.644 # | ||
| <4.0 g/dL | 14 (45.2) | 12 (36.4) | |
| Platelets | 0.543 # | ||
| <150 × 109/L | 9 (29.0) | 13 (39.4) | |
| Cholesterol (mmol/L) | (−2) | 0.942 # | |
| ≥200 mg/dL | 5 (16.1) | 7 (21.2) | |
| Antiviral treatment | 3 (9.7) | 8 (24.2) | 0.226 # |
| Fibrosis | |||
| Stage 0 | 7 (22.6) | 0 (0.0) | |
| Stage 1 | 17 (54.8) | 0 (0.0) | |
| Stage 2 | 7 (22.6) | 0 (0.0) | |
| Stage 3 | 0 (0.0) | 15 (45.5) | |
| Stage 4 | 0 (0.0) | 18 (54.6) |
Data are presented as N (%), mean ± SD. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; chronic hepatitis B, CHB; chronic hepatitis C, CHC; gamma glutamyl transferase, GGT; SD, standard deviation. # Chi squared test; ^ Fisher’s exact test; $ Student’s t-test. ** p-value < 0.01.